FDA CONSUMER HEALTH INFORMATION - Possible Fracture Risk With Osteoporosis Drug

SILVER SPRING, Md., Oct. 13 /PRNewswire-USNewswire/ --The Food and Drug Administration (FDA) is warning there is a possible risk of a rare type of thigh bone fracture in people who take drugs known as bisphosphonates to treat osteoporosis.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

The agency issued the warning because the rare type of fracture has been predominantly reported in patients taking these prescription medications.

Learn more about this warning, and what FDA advises you should do if you take these drugs, at http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm229127.htm.

Sign up for e-mail notices of new FDA Consumer Updates at:

https://service.govdelivery.com/service/subscribe.html?code=USFDA_9.

View the FDA Consumer Update RSS feed at: http://www.fda.gov/AboutFDA/ContactFDA/StayInformed/RSSFeeds/Consumers/rss.xml.

FDA Consumer Updates may be posted and published elsewhere without permission. Please credit "FDA Consumer Health Information (www.fda.gov/consumer)" as the source. FDA values feedback on its consumer health information. Send questions, comments, or story ideas to: [email protected].

Contact: Jason Brodsky, 1-301-796-8234, [email protected]

SOURCE U.S. Food and Drug Administration

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.